Progress in human tumour immunology and immunotherapy - PubMed (original) (raw)
Review
. 2001 May 17;411(6835):380-4.
doi: 10.1038/35077246.
Affiliations
- PMID: 11357146
- DOI: 10.1038/35077246
Review
Progress in human tumour immunology and immunotherapy
S A Rosenberg. Nature. 2001.
Abstract
Studies of the administration of interleukin-2 to patients with metastatic melanoma or kidney cancer have shown that immunological manipulations can mediate the durable regression of metastatic cancer. The molecular identification of cancer antigens has opened new possibilities for the development of effective immunotherapies for patients with cancer. Clinical studies using immunization with peptides derived from cancer antigens have shown that high levels of lymphocytes with anti-tumour activity can be raised in cancer-bearing patients. Highly avid anti-tumour lymphocytes can be isolated from immunized patients and grown in vitro for use in cell-transfer therapies. Current studies are aimed at understanding the mechanisms that enable the cancer to escape from immune attack.
Similar articles
- [Perspectives for tumour immunology: antigen-specific immunotherapy of malignant diseases].
Jäger E, Jäger D, Knuth A. Jäger E, et al. Dtsch Med Wochenschr. 2001 Sep 14;126(37):1011-6. doi: 10.1055/s-2001-17111. Dtsch Med Wochenschr. 2001. PMID: 11555776 Review. German. No abstract available. - Cancer vaccines: preclinical studies and novel strategies.
Palena C, Abrams SI, Schlom J, Hodge JW. Palena C, et al. Adv Cancer Res. 2006;95:115-45. doi: 10.1016/S0065-230X(06)95004-0. Adv Cancer Res. 2006. PMID: 16860657 Review. - The development of new cancer therapies based on the molecular identification of cancer regression antigens.
Rosenberg SA. Rosenberg SA. Cancer J Sci Am. 1995 Jul-Aug;1(2):90-100. Cancer J Sci Am. 1995. PMID: 9166458 Review. - Immunotherapy of melanoma.
Parmiani G, Castelli C, Rivoltini L, Casati C, Tully GA, Novellino L, Patuzzo A, Tosi D, Anichini A, Santinami M. Parmiani G, et al. Semin Cancer Biol. 2003 Dec;13(6):391-400. doi: 10.1016/j.semcancer.2003.09.001. Semin Cancer Biol. 2003. PMID: 15001157 Review. - [Immunotherapy for cancer--modern immunologic strategies in oncology].
Halama N, Zoernig I, Jäger D. Halama N, et al. Dtsch Med Wochenschr. 2008 Oct;133(41):2105-8. doi: 10.1055/s-0028-1091251. Epub 2008 Oct 1. Dtsch Med Wochenschr. 2008. PMID: 18985564 Review. German.
Cited by
- Feasibility and optimization of19F MRI on a clinical 3T with a large field-of-view torso coil.
Lechuga LM, Cho MM, Vail DM, Captini CM, Fain SB, Begovatz P. Lechuga LM, et al. Phys Med Biol. 2024 Jun 4;69(12):125002. doi: 10.1088/1361-6560/ad4d50. Phys Med Biol. 2024. PMID: 38759675 Free PMC article. - Haematologic biomarkers and survival in gallbladder cancer: a systematic review and meta-analysis.
Velasco RN Jr, Tan HNC, Juan MDS. Velasco RN Jr, et al. Ecancermedicalscience. 2024 Jan 30;18:1660. doi: 10.3332/ecancer.2024.1660. eCollection 2024. Ecancermedicalscience. 2024. PMID: 38425767 Free PMC article. Review. - Combined score based on plasma fibrinogen and platelet-lymphocyte ratio as a prognostic biomarker in esophageal squamous cell carcinoma.
Yang Y, Tan H, Lu Y, Mei J, Zhang M, Bai M, Wang X, Ge S, Ning T, Zhang L, Ji Z, Duan J, Sun Y, Wang F, Liu R, Li H, Deng T. Yang Y, et al. BMC Cancer. 2024 Feb 22;24(1):249. doi: 10.1186/s12885-024-11968-6. BMC Cancer. 2024. PMID: 38389042 Free PMC article. - Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapy.
Zheng A, Liu J, Liu Z, Mo Z, Fu Y, Deng Y, Jiang Y. Zheng A, et al. J Cancer Res Clin Oncol. 2024 Jan 31;150(2):58. doi: 10.1007/s00432-023-05575-4. J Cancer Res Clin Oncol. 2024. PMID: 38294686 Free PMC article. - Prognostic value of lymphocyte-to-monocyte ratio in gastric cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Mei P, Feng W, Zhan Y, Guo X. Mei P, et al. Front Immunol. 2023 Nov 27;14:1321584. doi: 10.3389/fimmu.2023.1321584. eCollection 2023. Front Immunol. 2023. PMID: 38090560 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources